AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 221 filers reported holding AMICUS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.76 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,807,657 | +73.4% | 148,656 | +79.1% | 0.00% | – |
| Q2 2023 | $1,042,467 | -83.8% | 82,999 | -85.7% | 0.00% | -100.0% |
| Q1 2023 | $6,444,133 | +85.0% | 581,076 | +103.7% | 0.00% | – |
| Q4 2022 | $3,483,501 | -82.4% | 285,299 | -85.0% | 0.00% | -100.0% |
| Q3 2022 | $19,800,000 | -51.5% | 1,896,559 | -50.1% | 0.00% | -60.0% |
| Q2 2022 | $40,792,000 | +168.6% | 3,798,140 | +136.8% | 0.01% | +233.3% |
| Q1 2022 | $15,187,000 | -22.7% | 1,603,773 | -5.7% | 0.00% | -25.0% |
| Q4 2021 | $19,638,000 | -35.5% | 1,700,202 | -46.7% | 0.00% | -33.3% |
| Q3 2021 | $30,462,000 | +96.8% | 3,189,794 | +98.6% | 0.01% | +100.0% |
| Q2 2021 | $15,480,000 | +52.9% | 1,605,799 | +56.6% | 0.00% | 0.0% |
| Q1 2021 | $10,127,000 | -16.7% | 1,025,103 | +94.6% | 0.00% | 0.0% |
| Q4 2020 | $12,163,000 | -13.5% | 526,783 | -47.1% | 0.00% | -25.0% |
| Q3 2020 | $14,064,000 | -53.9% | 996,131 | -50.7% | 0.00% | -63.6% |
| Q2 2020 | $30,486,000 | +46.4% | 2,021,601 | -10.3% | 0.01% | +22.2% |
| Q1 2020 | $20,821,000 | -46.4% | 2,253,328 | -43.5% | 0.01% | -43.8% |
| Q4 2019 | $38,821,000 | -1.2% | 3,985,699 | -18.6% | 0.02% | -11.1% |
| Q3 2019 | $39,273,000 | -37.1% | 4,896,927 | -2.1% | 0.02% | -35.7% |
| Q2 2019 | $62,410,000 | -29.3% | 5,000,809 | -23.0% | 0.03% | -36.4% |
| Q1 2019 | $88,315,000 | +820.5% | 6,493,814 | +548.5% | 0.04% | +780.0% |
| Q4 2018 | $9,594,000 | +95.0% | 1,001,436 | +146.1% | 0.01% | +150.0% |
| Q3 2018 | $4,919,000 | +77.6% | 406,972 | +129.5% | 0.00% | +100.0% |
| Q2 2018 | $2,770,000 | -78.7% | 177,300 | -79.5% | 0.00% | -85.7% |
| Q1 2018 | $12,996,000 | -76.9% | 864,169 | -77.9% | 0.01% | -80.0% |
| Q4 2017 | $56,292,000 | +78.7% | 3,911,868 | +87.3% | 0.04% | +40.0% |
| Q3 2017 | $31,499,000 | +8.9% | 2,088,858 | -27.3% | 0.02% | +4.2% |
| Q2 2017 | $28,918,000 | +179.0% | 2,871,788 | +97.6% | 0.02% | +166.7% |
| Q1 2017 | $10,364,000 | +423.4% | 1,453,557 | +264.9% | 0.01% | +350.0% |
| Q4 2016 | $1,980,000 | -38.9% | 398,351 | -9.0% | 0.00% | -33.3% |
| Q3 2016 | $3,238,000 | +2.1% | 437,541 | -24.7% | 0.00% | -25.0% |
| Q2 2016 | $3,172,000 | +1788.1% | 580,934 | +3249.7% | 0.00% | – |
| Q4 2015 | $168,000 | -99.7% | 17,343 | -99.6% | 0.00% | -100.0% |
| Q3 2015 | $59,839,000 | +6.6% | 4,277,283 | +7.9% | 0.06% | +16.3% |
| Q2 2015 | $56,109,000 | +31.6% | 3,965,272 | +1.2% | 0.05% | +22.5% |
| Q1 2015 | $42,650,000 | +118.2% | 3,920,077 | +66.8% | 0.04% | +110.5% |
| Q4 2014 | $19,548,000 | +10466.5% | 2,349,515 | +7449.4% | 0.02% | – |
| Q3 2014 | $185,000 | +585.2% | 31,122 | +175.9% | 0.00% | – |
| Q4 2013 | $27,000 | +58.8% | 11,281 | +51.7% | 0.00% | – |
| Q3 2013 | $17,000 | -63.8% | 7,436 | -63.0% | 0.00% | – |
| Q2 2013 | $47,000 | – | 20,086 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |